PIA
RXRX icon

Powell Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Powell Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
33,660
+2,964
+10% +$9.87K 0.04% 137
2026
Q1 		$94.2K Buy
30,696
+1,000
+3% +$3.86K 0.03% 152
2025
Q4 		$121K Buy
29,696
+18,089
+156% +$89.6K 0.04% 145
2025
Q3 		$56.6K Sell
11,607
-8,423
-42% -$44.2K 0.02% 157
2025
Q2 		$101K Buy
+20,030
New +$98.4K 0.04% 142

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Powell Investment Advisors's RXRX Position: Q2 2026 in Review

Powell Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 9.7% in Q2 2026, buying an estimated $9.87K and bringing the position to 33,660 shares worth $124K. The position accounts for 0.04% of the portfolio, ranked #137.

Powell Investment Advisors first reported a position in RXRX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Powell Investment Advisors held 33,660 shares of Recursion Pharmaceuticals worth $124K as of Q2 2026.
  • Powell Investment Advisors bought 2,964 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.87K.
  • Recursion Pharmaceuticals made up 0.04% of Powell Investment Advisors's portfolio in Q2 2026, its #137 holding.
  • Powell Investment Advisors first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Powell Investment Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.